MicroOptx Pursues New MIGS Approach
Chris Pulling, CEO of MicroOptx, tells OISTV about its Brown Glaucoma Implant (new name pending). The implant is used to lower IOP by draining aqueous fluid. Unlike other implants, which divert fluid to other chambers of the eye, MicroOptx is shunts the fluid to the tear film.
Chris was most recently CEO of The Integra Group, a contract medical research organization he founded in 2002, until its recent successful sale to the world’s largest organization in the medical device sector.